for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evolus Inc

EOLS.OQ

Latest Trade

5.83USD

Change

0.18(+3.19%)

Volume

96,744

Today's Range

5.46

 - 

5.88

52 Week Range

2.85

 - 

11.72

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.65
Open
5.66
Volume
96,744
3M AVG Volume
14.29
Today's High
5.88
Today's Low
5.46
52 Week High
11.72
52 Week Low
2.85
Shares Out (MIL)
33.75
Market Cap (MIL)
196.76
Forward P/E
-3.00
Dividend (Yield %)
--

Next Event

Evolus Inc Annual Shareholders Meeting

Latest Developments

More

Evolus Inc - On January 4, Co, Oxford Finance Entered Into A Payoff Letter Agreement - SEC Filing

Evolus Inc - On December 16, 2020, ITC Issued Its Final Determination In ITC Action

Evolus Reports Third Quarter 2020 Results And Provides Business Update

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Evolus Inc

Evolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

Industry

Biotechnology & Drugs

Contact Info

520 Newport Center Dr Ste 1200

NEWPORT BEACH, CA

92660-7022

United States

+1.949.2844555

https://www.evolus.com

Executive Leadership

Vikram Malik

Chairman of the Board

David Moatazedi

President, Chief Executive Officer, Director

Lauren P. Silvernail

Chief Financial Officer, Executive Vice President - Corporate Development

Jeff Plumer

General Counsel

Rui L. Avelar

Chief Medical Officer, Head of Research & Development

Key Stats

2.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (USD)

2017

-0.310

2018

-1.920

2019

-2.560

2020(E)

-1.883
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.55
Price To Book (MRQ)
5.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
378.85
LT Debt To Equity (MRQ)
378.85
Return on Investment (TTM)
-37.15
Return on Equity (TTM)
-33.54

Latest News

Latest News

BRIEF-Evolus Says Daewoong Pharmaceutical to invest $40 Million in Co

* EVOLUS STRENGTHENS BALANCE SHEET; SECURES $40 MILLION INVESTMENT

BRIEF-Evolus Provides Update On United States International Trade Commission (USITC) Case

* EVOLUS PROVIDES UPDATE ON UNITED STATES INTERNATIONAL TRADE COMMISSION (USITC) CASE

BRIEF-Evolus Says Administrate Law Judge Extended Target Date For Initial Determination Regarding ITC Action

* EVOLUS - ON JUNE 1, ADMINISTRATE LAW JUDGE ASSIGNED TO ITC ACTION ISSUED DECISION EXTENDING TARGET DATE FOR INITIAL DETERMINATION BY JUDGE TO JULY 6

BRIEF-Evolus Reports First Quarter 2020 Results

* EVOLUS REPORTS FIRST QUARTER 2020 RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Evolus Inc Reducing Headcount By Over 100 Employees

* EVOLUS INC - REDUCTION IN COMPANY'S HEADCOUNT BY OVER 100 EMPLOYEES, WHICH REPRESENT A REDUCTION FROM 235 EMPLOYEES AS OF DECEMBER 31, 2019

BRIEF-Evolus Provides Strategic Business Update

* EVOLUS INC - WE PLAN TO INTRODUCE A NEW STIMULUS PROGRAM, EXECUTED THROUGH OUR FULLY INTEGRATED DIGITAL PLATFORM

BRIEF-Evolus Provides Update On International Trade Commission Case

* EVOLUS PROVIDES UPDATE ON INTERNATIONAL TRADE COMMISSION (ITC) CASE

Evolus reports sales of its Botox rival ahead of expectations

Medical aesthetics company Evolus Inc <EOLS.O> on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's <AGN.N> Botox, which has dominated the medical aesthetics market for more than a decade.

Evolus says launch of its Botox rival ahead of its expectations

Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.

FDA approves cheaper Botox rival to treat frown lines

(This Feb. 1 story has been corrected to remove reference to dosage in paragraph 7)

BRIEF-Evolus Announces Pricing Of Initial Public Offering Of Common Stock

* EVOLUS, INC. ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF COMMON STOCK

BRIEF-Evolus Inc Sees IPO Priced To Be Between $12 And $14 Per Share

* EVOLUS INC SEES IPO OF 5 MILLION SHARES PRICED TO BE BETWEEN $12 AND $14 PER SHARE – SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up